Results for this period
First quarter1 January 2026–31 March 2026ConsolidatedIFRSThe width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit. The dotted outline is the full-year forecast and the band inside it is the result for this period. The progress rate is the result divided by the forecast.
塗りつぶした部分が自己資本比率です。総資産のうち、返済のいらない自前の資金がどれだけかを表します。The thin vertical line indicates the level at the end of the previous fiscal year.
Stacked from zero: upward is an increase in cash, downward a decrease (in ¥ million).The net change represented by the dotted line is the total of three items, calculated from figures provided by the company.
The company focused on developing high-value-added products in oral healthcare, while net sales and business profit in the overseas business increased. In the consumer products business, business profit declined because the company made proactive advertising and promotional investments, centered on priority brands.
No applicable matters. The filing states, "There are no applicable matters."
| Item | Details |
|---|---|
| Fiscal Period Classification | First quarter |
| Accounting standards | IFRS |
| Consolidated / non-consolidated | Consolidated |
| Period Covered | 1 January 2026–31 March 2026 |
| Net Sales | ¥99,205 million (YoY +5.3%) |
| Operating profit | ¥6,292 million (YoY +11.6%) |
| Ordinary income | ¥7,392 million (YoY +16.9%) |
| Profit attributable to owners of the parent | ¥4,206 million (YoY +4.5%) |
| Net income per share | ¥15.21 |
| Equity ratio | End of the current fiscal period 62.1 / End of previous period 61.1 |
| Total assets | ¥520,307 million |
| Net assets | ¥349,708 million |
| Cash flows from operating activities | ¥-10,868 million |
| Cash flows from investing activities | ¥-17,792 million |
| Cash flows from financing activities | ¥-1,231 million |
| Cash and cash equivalents at end of period | ¥58,424 million |
| Full-year earnings forecast | Net Sales ¥430,000 million (YoY +1.9%) / Operating profit ¥40,000 million (YoY +10.0%) / Ordinary income Not disclosed / Net income ¥25,000 million (YoY -9.4%) |
| Annual Dividend Forecast | ¥30 → ¥34（+13.3%） |
| Segment revenue | Consumer products business ¥57,372 million (YoY +3.6%), Industrial Products Business ¥13,233 million (YoY -6.5%), Overseas Operations ¥46,989 million (YoY +10.7%), Other ¥1,387 million (YoY -49.8%) |
| Segment profit | Consumer products business ¥4,063 million (YoY -8.1%), Industrial Products Business ¥653 million (YoY -0.2%), Overseas Operations ¥2,895 million (YoY +60.7%), Other ¥-45 million |
| Regional sales | ¥31,131 million (YoY +18.8%), ¥15,857 million (YoY -2.5%) |
| Depreciation and amortization | ¥5,660 million |
| Impairment loss | None recorded in the current first quarter (cash flow statement: “—”) |
| Disclosure regarding the going concern assumption | No applicable matters. The filing states, "There are no applicable matters." |
| Change in accounting policy | Changes due to revisions to standards No / Other changes No / Change in accounting estimate No / Restatement Not disclosed |
| Changes in the scope of consolidation | New Number of companies 8 / Company name PNB Consolidated Pty Ltd and others / Excluded Not disclosed |
| Availability of Supplementary Financial Results Materials | Yes |
| Availability of Financial Results Briefing | Whether applicable Yes / Subject person Institutional investors, securities analysts and others |
| Issued Shares at Period-End | 279,782,746 |
| Treasury Shares at Period-End | 3,116,125 |
| Factors Behind Changes in Business Performance | The company focused on developing high-value-added products in oral healthcare, while net sales and business profit in the overseas business increased. In the consumer products business, business profit declined because the company made proactive advertising and promotional investments, centered on priority brands. |
Items this document does not state (7)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The company focused on developing high-value-added products in oral healthcare, while net sales and business profit in the overseas business increased. In the consumer products business, however, business profit declined because the company made proactive advertising and promotional investments, centered on priority brands.